Theravance Biopharma Dirección
Dirección controles de criterios 3/4
El CEO de Theravance Biopharma es Rick Winningham , nombrado en Jun 2014, tiene una permanencia de 10.42 años. compensación anual total es $4.32M, compuesta por 24.3% salario y 75.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 3.88% de las acciones de la empresa, por valor de $18.06M. La antigüedad media del equipo directivo y de la junta directiva es de 2.4 años y 6.8 años, respectivamente.
Información clave
Rick Winningham
Chief Executive Officer (CEO)
US$4.3m
Compensación total
| Porcentaje del salario del CEO | 24.3% |
| Permanencia del CEO | 10.4yrs |
| Participación del CEO | 3.9% |
| Permanencia media de la dirección | 2.4yrs |
| Promedio de permanencia en la Junta Directiva | 6.8yrs |
Actualizaciones recientes de la dirección
Recent updates
With Theravance Biopharma, Inc. (NASDAQ:TBPH) It Looks Like You'll Get What You Pay For
Nov 12
We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow
Jul 16Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now
May 02Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S
Feb 05Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts
Nov 11Theravance to purchase $95M of ordinary shares
Sep 28Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade
Sep 21Theravance Biopharma announces $250M capital return program
Sep 19Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M
Aug 04Theravance: All-Round Failure
Mar 10Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%
Aug 09Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study
Jun 21Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year
May 09Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$49m |
| Jun 30 2024 | n/a | n/a | -US$46m |
| Mar 31 2024 | n/a | n/a | -US$45m |
| Dec 31 2023 | US$4m | US$1m | -US$55m |
| Sep 30 2023 | n/a | n/a | -US$61m |
| Jun 30 2023 | n/a | n/a | -US$68m |
| Mar 31 2023 | n/a | n/a | -US$75m |
| Dec 31 2022 | US$6m | US$1m | -US$93m |
| Sep 30 2022 | n/a | n/a | -US$136m |
| Jun 30 2022 | n/a | n/a | -US$196m |
| Mar 31 2022 | n/a | n/a | -US$226m |
| Dec 31 2021 | US$4m | US$1m | -US$265m |
| Sep 30 2021 | n/a | n/a | -US$266m |
| Jun 30 2021 | n/a | n/a | -US$264m |
| Mar 31 2021 | n/a | n/a | -US$275m |
| Dec 31 2020 | US$7m | US$1m | -US$295m |
| Sep 30 2020 | n/a | n/a | -US$285m |
| Jun 30 2020 | n/a | n/a | -US$270m |
| Mar 31 2020 | n/a | n/a | -US$247m |
| Dec 31 2019 | US$6m | US$984k | -US$236m |
| Sep 30 2019 | n/a | n/a | -US$221m |
| Jun 30 2019 | n/a | n/a | -US$222m |
| Mar 31 2019 | n/a | n/a | -US$223m |
| Dec 31 2018 | US$3m | US$957k | -US$216m |
| Sep 30 2018 | n/a | n/a | -US$252m |
| Jun 30 2018 | n/a | n/a | -US$260m |
| Mar 31 2018 | n/a | n/a | -US$285m |
| Dec 31 2017 | US$2m | US$933k | -US$285m |
Compensación vs. Mercado: La compensación total de Rick($USD4.32M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.22M).
Compensación vs. Ingresos: La compensación de Rick ha sido consistente con los resultados de la empresa en el último año.
CEO
Rick Winningham (64 yo)
10.4yrs
Permanencia
US$4,318,531
Compensación
Mr. Rick E. Winningham, M.B.A., served as Chairman of Retrotope Inc. since February 2021 until January 2022. He serves as Director at Rivus Pharmaceuticals, Inc. since 2024. He has been Lead Independent Di...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 10.4yrs | US$4.32m | 3.88% $ 18.1m | |
| Senior VP & CFO | 1.8yrs | US$1.39m | 0.64% $ 3.0m | |
| Senior VP of IT&I and Chief Information Officer | no data | sin datos | sin datos | |
| Vice President of Corporate Communications & Investor Relations | no data | sin datos | sin datos | |
| Senior VP | 2.4yrs | sin datos | 0.68% $ 3.2m | |
| Chief Business Officer and Senior VP of Commercial & Medical Affairs | 2.9yrs | US$942.81k | 0.64% $ 3.0m | |
| Senior VP & Chief Strategy Officer | 2.2yrs | sin datos | sin datos | |
| SVP of Dev. | no data | sin datos | 0.31% $ 1.4m |
2.4yrs
Permanencia media
54.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de TBPH se considera experimentado (2.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 11.3yrs | US$4.32m | 3.88% $ 18.1m | |
| Independent Director | 10.4yrs | US$205.14k | 0.14% $ 663.1k | |
| Independent Director | 4.3yrs | US$207.68k | 0.096% $ 449.0k | |
| Lead Independent Director | 10.4yrs | US$211.73k | 0.16% $ 762.9k | |
| Independent Director | 1.6yrs | US$43.10k | sin datos | |
| Independent Director | 9.1yrs | US$195.80k | 0.13% $ 601.8k | |
| Independent Chairman | 1.8yrs | US$346.47k | 0.064% $ 298.2k | |
| Independent Director | 6.8yrs | US$197.68k | 0.13% $ 609.2k | |
| Independent Director | less than a year | US$168.36k | 0.045% $ 211.2k |
6.8yrs
Permanencia media
64.5yo
Promedio de edad
Junta con experiencia: La junta directiva de TBPH se considera experimentada (6.8 años de antigüedad promedio).